↓ Skip to main content

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers…

Overview of attention for article published in BMC Cancer, March 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

peer_reviews
1 peer review site

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
65 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
Published in
BMC Cancer, March 2019
DOI 10.1186/s12885-019-5498-3
Pubmed ID
Authors

Maria Di Bartolomeo, Monica Niger, Federica Morano, Salvatore Corallo, Maria Antista, Stefano Tamberi, Sara Lonardi, Samantha Di Donato, Rossana Berardi, Mario Scartozzi, Giovanni Gerardo Cardellino, Francesco Di Costanzo, Lorenza Rimassa, Alberto Gianluigi Luporini, Raffaella Longarini, Alberto Zaniboni, Alessandro Bertolini, Gianluca Tomasello, Graziella Pinotti, Giorgio Scagliotti, Giampaolo Tortora, Andrea Bonetti, Andrea Spallanzani, Giovanni Luca Frassineti, Davide Tassinari, Francesco Giuliani, Saverio Cinieri, Evaristo Maiello, Claudio Verusio, Sergio Bracarda, Vincenzo Catalano, Michele Basso, Libero Ciuffreda, Ferdinando De Vita, Hector Soto Parra, Lorenzo Fornaro, Marta Caporale, Filippo de Braud, Filippo Pietrantonio

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 8 12%
Student > Bachelor 7 11%
Unspecified 4 6%
Other 4 6%
Student > Ph. D. Student 4 6%
Other 13 20%
Unknown 25 38%
Readers by discipline Count As %
Medicine and Dentistry 19 29%
Nursing and Health Professions 4 6%
Unspecified 4 6%
Biochemistry, Genetics and Molecular Biology 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Other 8 12%
Unknown 24 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2019.
All research outputs
#15,567,535
of 23,138,859 outputs
Outputs from BMC Cancer
#4,167
of 8,396 outputs
Outputs of similar age
#219,336
of 351,128 outputs
Outputs of similar age from BMC Cancer
#101
of 194 outputs
Altmetric has tracked 23,138,859 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,396 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,128 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 194 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.